Anticipating and managing the challenges of biotechnology marketing

Journal of Commercial Biotechnology

Volumn 14, Issue 3, 2008, Pages 225-231

  Rajamäki, Heidi ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCONVERSION; BIOTECHNOLOGY; ESTIMATION; EVOLUTIONARY ALGORITHMS; INDUSTRY; INNOVATION; INTELLECTUAL PROPERTY; LAWS AND LEGISLATION; MARKETING; OBSOLESCENCE; RISK PERCEPTION; TECHNOLOGY;

BIOTECHNOLOGY COMPANIES; INTELLECTUAL PROPERTY RIGHTS (IPRS); LIFE CYCLE (LC); MARKET POTENTIAL; MARKET UNCERTAINTIES; POTENTIAL MARKETS; POTENTIAL RISKS; PREMATURE DEATH; PRODUCT INNOVATION MANAGEMENT; PRODUCT LINES; RAPID RATE; SIDE EFFECTS; SOLID BASE; TECHNOLOGICAL UNCERTAINTY;

CHEMICALS;

ALPHA INTERFERON; CITALOPRAM; ERYTHROPOIETIN; FLUOXETINE; FLUVOXAMINE; GENERIC DRUG; HUMAN GROWTH HORMONE; NEW DRUG; PAROXETINE; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; SERTRALINE;

ARTICLE; CARDIOVASCULAR DISEASE; COMMERCIAL PHENOMENA; COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; DRUG NOMENCLATURE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GENE TECHNOLOGY; MEDICAL TECHNOLOGY; PATENT; PRODUCT DEVELOPMENT; PROFIT; SHELF LIFE; UNCERTAINTY;

EID: 46649102240     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/jcb.2008.13     Document Type: Article

References (26)

1. Grupp, R. W. & Gaines-Ross, L. (2002). Reputation management in the biotechnology industry. J. Comm. Biotechnol. 9(1), 17-26.
2. Rodgers, P., Carton, D. & Duncan, G. S. (2002). Practical experiences in starting up life science companies in the academic sector. J. Comm. Biotechnol. 8(4), 273-280.
3. Campbell, A. F. (2005). The evolving concept of value add in university commercialisation. J. Comm. Biotechnol. 11(4), 337-345.
4. Renko, M. (2006). Market Orientation in Markets for Technology-Evidence from Biotechnology Ventures, Turku School of Economics, Turku.
5. Costa, C., Fontes, M. & Heitor, M. (2004). A methodological approach to the marketing process in the biotechnology-based companies. Ind. Market. Manage. 33, 403-418.
6. Williams, A. (2005). Corporate development in biotechnology in 2005. J. Comm. Biotechnol. 11(3), 239-248.
7. Hermans, R., Kulvik, M. & Tahvanainen, A. (2005). Etla 2004 survey on the Finnish biotechnology industry - Background and descriptive statistics. Etla Discuss. Pap. 978, 1-40.
8. Remer, S., Ang, S. H. & Baden-Fuller, C. (2001). Dealing with uncertainties in the biotechnology industry: The use of real options reasoning. J. Comm. Biotechnol. 8(2), 95-105.
9. Moriarty, R. T. & Kosnik, T. J. (1989). High-tech marketing: Concepts, continuity, and change. Sloan Manage. Rev. 30, 7-17.
10. Levitt, T. (1975). Marketing myopia. Harvard Bus. Rev. 38(4), 26.
11. Fazeli, S. (2005). The European biotech sector: Could it achieve more? J. Comm. Biotechnol. 12(1), 10-19.
12. McKenna, R. (1989). Why high-tech products fail', in Smilor, R.W. (eds.), Customer Driven Marketing: Lessons from Entrepreneurial Technology Companies, Lexington Books, Lexington, MA, pp. 3-14.
13. Robertson, T. S. & Gatignon, H. (1986). Competitive effects on technology diffusion. J. Market. 50, 1-12.
14. Pisano, G. P. (2006). Can science be a business? Lessons from biotech. Harvard Bus. Rev. 8410, 114-125.
15. Resnik, D. B. (2004). Fair drug prices and patent system. Health Care Anal. 12(2), 91-114.
16. Mullis, K. B. (1987). Process for amplifying nucleic acid sequences', US Patent number 4683202.
17. Mullis, K. B., Erlich, H. A., Gelfand, D. H., Horn, G. & Saiki, R. K. (1987). Process for amplifying, detecting, and/or-cloning nucleic acid sequences', US Patent number 4683195.
18. Mullis, K. B., Erlich, H. A., Arnheim, A., Horn, G. T., Saiki, R. K. & Scarf, S. J. (1989). Process for amplifying, detecting, and/or cloning nucleic acid sequences', US Patent number 4800159.
19. Schmid, E. F. & Smith, D. A. (2005). Managing innovation in the pharmaceutical industry. J. Comm. Biotechnol. 12(1), 50-57.
20. McIntyre, L. (2002). Forecasting new product revenues. J. Comm. Biotechnol. 8(4), 289-297.
21. McMurray, A. & Jones, R. (2003). A new model to evaluate the market for biotechnology. J. Comm. Biotechnol. 10(1), 78-84.
22. Valentine, E. L. (2003). Business development: A barometer of future success. J. Comm. Biotechnol. 10(2), 123-130.
23. Abetti, P. A. (1985). Milestones for managing technological innovation. Plan. Rev. 13(2), 18-46.
24. Dalen, D. M., Strøm, S. & Haabeth, T. (2006). Price regulation and generic competition in the pharmaceutical market. Eur. J. Health Econ. 7(3), 208-214.
25. Kapner, V. & Chory, J. (2002). Pitfalls to avoid when starting a biotechnology company in the USA. J. Comm. Biotechnol. 8 (4), 281-288.
26. Teece, D. J. (1986). Profiting from technological innovation: Implications for integration, collaboration, licencing and public policy. Res. Pol. 15, 285-305.